Concerning Ph-like ALL with JAK/STAT pathway lesions, the addition of Ruxolitinib (a JAK inhibitor) to combination chemotherapy to treat pediatric patients is currently tested in three clinical trials (NCT03117751; NCT02723994; NCT02420717). The gene discussed is SOAT1; the disease is acute lymphoblastic leukemia.